AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8669568 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 8669568 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 1997239 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 24 hours
Number of subjects: 41
Study 1997239 — intervention group
Group type: COMPARATOR
Intervention: Closed suction drainage for 48 hours
Number of subjects: 41
Study 6385314 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy with antrectomy (SVA)
Number of subjects: 86
Study 6385314 — intervention group
Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 86
Study 31124309 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette describing CHR affecting family obligations
Number of subjects: 215
Study 31124309 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette describing CHR symptomology only
Number of subjects: 215
Study 31124309 — intervention group
Group type: COMPARATOR
Intervention: Vignette describing CHR affecting individual aspirations
Number of subjects: 215
Study 31340611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosed milk protein hydrolysate
Number of subjects: 0
Study 31340611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28507373 — intervention group
Group type: EXPERIMENTAL
Intervention: LASER therapy
Number of subjects: 38
Study 28507373 — intervention group
Group type: COMPARATOR
Intervention: Interferential current
Number of subjects: 38
Study 25854019 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture combined with auricular point sticking
Number of subjects: 85
Study 25854019 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine hydrochloride capsules orally
Number of subjects: 85
Study 23970774 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interview (ACASI)
Number of subjects: 0
Study 23970774 — intervention group
Group type: COMPARATOR
Intervention: Self-administered paper-based interview (SAPI)
Number of subjects: 0
Study 23970774 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview (FFI)
Number of subjects: 0
Study 23970774 — intervention group
Group type: COMPARATOR
Intervention: Sexually transmitted infections (STIs)
Number of subjects: 0
Study 21148662 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 318
Study 21148662 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (CCB)
Number of subjects: 318
Study 19072714 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 363
Study 19072714 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (Control)
Number of subjects: 363
Study 16414557 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 82
Study 16414557 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention
Number of subjects: 82
Study 16414557 — intervention group
Group type: COMPARATOR
Intervention: Second Cold Pressor Test
Number of subjects: 82
Study 15313296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 90
Study 15313296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% drops
Number of subjects: 90
Study 15313296 — intervention group
Group type: COMPARATOR
Intervention: Benoxinate 0.4% drops
Number of subjects: 90
Study 11275879 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic suturing device
Number of subjects: 64
Study 9494172 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy for stroke prevention
Number of subjects: 0
Study 9494172 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 0
Study 8359787 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.5 IU/kg/week
Number of subjects: 161
Study 8359787 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1.0 IU/kg/week
Number of subjects: 161
Study 8359787 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 161
Study 3463544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 X 400 mg enoxacin
Number of subjects: 120
Study 3463544 — intervention group
Group type: COMPARATOR
Intervention: 1 X 3 g amoxicillin
Number of subjects: 120
Study 3463544 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxacin
Number of subjects: 120
Study 3463544 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin
Number of subjects: 120
Study 31857230 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS 1 + ESB
Number of subjects: 40
Study 31857230 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS 2
Number of subjects: 40
Study 31857230 — intervention group
Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 40
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-retained with submucosal veneering (CR-P)
Number of subjects: 44
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-retained without submucosal veneering (CR-W)
Number of subjects: 44
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained with submucosal veneering (SR-P)
Number of subjects: 44
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained without submucosal veneering (SR-W)
Number of subjects: 44
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-retained groups (CR-P and CR-W)
Number of subjects: 44
Study 30328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained groups (SR-P and SR-W)
Number of subjects: 44
Study 26500075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using 100 mg/m2 of cisplatin for 90 min
Number of subjects: 8
Study 26500075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 8
Study 24772619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intrapelvic chemotherapy with hyperthermia (cisplatin at a dose of 150 mg, duration 60 minutes, temperature 44-45 degrees C)
Number of subjects: 120
Study 24772619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intrapelvic chemotherapy with hyperthermia
Number of subjects: 120
Study 24772619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative intrapelvic chemotherapy with hyperthermia)
Number of subjects: 120
Study 22323575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (n=48)
Number of subjects: 308
Study 22323575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=52)
Number of subjects: 308
Study 22323575 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 308
Study 20226430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle advice
Number of subjects: 66
Study 18923067 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0777 (benzodiazepine-like agent with selective activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits)
Number of subjects: 15
Study 18923067 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0777
Number of subjects: 15
Study 18923067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15580479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 5220
Study 15580479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5220
Study 11315842 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (GHb) levels categorized as optimal to moderate (GHb ≤ 9%)
Number of subjects: 89
Study 11315842 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal glycemic control (GHb > 9%)
Number of subjects: 89
Study 11315842 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 89
Study 11315842 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 89
Study 9586597 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study 9586597 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blockers
Number of subjects: 0
Study 9586597 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term medical therapy for BPH
Number of subjects: 0
Study 7635032 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 200000
Study 7635032 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of antiepileptic drugs
Number of subjects: 200000
Study 2681020 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor and medical care changes
Number of subjects: 0
Study 2681020 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic and innovative surveillance research
Number of subjects: 0
Study 779871 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bone marrow transplantation (performed 17-100 days after diagnosis)
Number of subjects: 67
Study 779871 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (transfusion support with or without androgens)
Number of subjects: 67
Study 779871 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bone marrow transplantation
Number of subjects: 67
Study 30853517 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP Group (n = 30) received ultrasound-guided bilateral ESP block with 0.25% bupivacaine 20 mL
Number of subjects: 60
Study 30853517 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP Group (n = 30)
Number of subjects: 60
Study 30853517 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 30)
Number of subjects: 60
Study 28596448 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable nitrate intake
Number of subjects: 1226
Study 25280910 — intervention group
Group type: EXPERIMENTAL
Intervention: High contact force (CF) ≥22 g
Number of subjects: 100
Study 25280910 — intervention group
Group type: COMPARATOR
Intervention: Low contact force (CF) <22 g
Number of subjects: 100
Study 23183941 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 420
Study 23183941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 21602718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at a mean dose of 16 mg/kg/d
Number of subjects: 152
Study 21602718 — intervention group
Group type: COMPARATOR
Intervention: Control group (transfusion requirement during the 6 months preceding the study)
Number of subjects: 152
Study 19384935 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU group (deep sedation and artificial respiration)
Number of subjects: 100
Study 19384935 — intervention group
Group type: COMPARATOR
Intervention: Recovery room group (spontaneous breathing without sedation)
Number of subjects: 100
Study 16342302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 392
Study 16342302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 392
Study 15312253 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 43
Study 11190708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 mg slow-release)
Number of subjects: 96
Study 11190708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8817980 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMedicus pump and distal aortic perfusion with cerebral spinal fluid drainage
Number of subjects: 0
Study 1462022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (320 micrograms day‐1)
Number of subjects: 14
Study 3882368 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) during period 1 (wk 1-13)
Number of subjects: 16
Study 3882368 — intervention group
Group type: COMPARATOR
Intervention: Urine testing only during period 2 (wk 14-26)
Number of subjects: 16
Study 3882368 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) confirmed symptoms of hypoglycemia in all children and detected asymptomatic hypoglycemia (BG <= 40 mg/dl) in 11 children.
Number of subjects: 16
Study 3882368 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 16
Study 29763609 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous use of oxytocin and cervical ripening balloon
Number of subjects: 180
Study 29763609 — intervention group
Group type: COMPARATOR
Intervention: Sequential use of oxytocin following cervical ripening balloon expulsion
Number of subjects: 180
Study 28101753 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem combined with paroxetine (combined treatment group, n = 45)
Number of subjects: 90
Study 28101753 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem combined with placebo (control group, n = 45)
Number of subjects: 90
Study 26137616 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing iodized salt from diet
Number of subjects: 911
Study 23761390 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg on days 1-3, 20 mg on days 4-24, 10 mg on days 25-28)
Number of subjects: 23
Study 23761390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23761390 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 23
Study 21165728 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideRite(®) Rigid Stylet (GRS)
Number of subjects: 60
Study 21165728 — intervention group
Group type: COMPARATOR
Intervention: Standard malleable stylet (SMS)
Number of subjects: 60
Study 18347488 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management services by telephone or in person for 4 months
Number of subjects: 88
Study 18347488 — intervention group
Group type: COMPARATOR
Intervention: List of community resources (Control)
Number of subjects: 88
Study 18347488 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 88
Study 16340629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip treatment
Number of subjects: 77
Study 14550800 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC transplantation (PBPCT)
Number of subjects: 120
Study 14550800 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 120
Study 10825787 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Mometasone Furoate
Number of subjects: 0
Study 9053107 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal meningitidis vaccination
Number of subjects: 0
Study 1463259 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 29
Study 6389909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of dihydroergotamine plus 5000 IU of sodium heparin (DHE 5000)
Number of subjects: 0
Study 6389909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of dihydroergotamine plus 2500 IU heparin (DHE 2500)
Number of subjects: 0
Study 6389909 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU of heparin (HEP 5000)
Number of subjects: 0
Study 6389909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of dihydroergotamine (DHE 0.5)
Number of subjects: 0
Study 6389909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4059716 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29089267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based therapy (esomeprazole 20mg b.i.d and Pylera 3 tablets q.i.d)
Number of subjects: 187
Study 29089267 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (esomeprazole 20mg plus amoxicillin 1,000mg, clarithromycin 500mg and tinidazole 500mg, all b.i.d.)
Number of subjects: 187
Study 29089267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (esomeprazole 20mg plus amoxicillin 1,000mg for 5 days followed by esomeprazole 20mg plus clarithromycin 500mg and tinidazole 500mg for 5 days, all b.i.d.)
Number of subjects: 187
Study 26681570 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial flap turbinoplasty
Number of subjects: 100
Study 26681570 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 100
Study 26681570 — intervention group
Group type: COMPARATOR
Intervention: Submucosal powered turbinate reduction
Number of subjects: 100
Study 24713367 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal vaccine
Number of subjects: 260700
Study 24713367 — intervention group
Group type: COMPARATOR
Intervention: Introduction letters sent on behalf of general practitioners
Number of subjects: 260700
Study 24330472 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention targeting neonatal health
Number of subjects: 0
Study 24330472 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention
Number of subjects: 0
Study 21080804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 0
Study 21080804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18515945 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs targeting lower extremity muscular strength, balance, and walking speed
Number of subjects: 0
Study 18515945 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 16864164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF-type chemotherapy (CT)
Number of subjects: 1226
Study 16864164 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 1226
Study 14620302 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN) and active stretching exercises (G1)
Number of subjects: 40
Study 14620302 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises alone (G2)
Number of subjects: 40
Study 14620302 — intervention group
Group type: COMPARATOR
Intervention: No treatment controls (G3)
Number of subjects: 40
Study 11068346 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology examination by two blinded reflexologists
Number of subjects: 18
Study 11068346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment
Number of subjects: 18
Study 9002803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin etched with 10% phosphoric acid for 20 seconds
Number of subjects: 24
Study 9002803 — intervention group
Group type: COMPARATOR
Intervention: Dentin protected by a light-cured glass ionomer liner
Number of subjects: 24
Study 9002803 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 24
Study 1736548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin and orbital radiotherapy (Group 1)
Number of subjects: 14
Study 1736548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin alone (Group 2)
Number of subjects: 14
Study 1736548 — intervention group
Group type: COMPARATOR
Intervention: Systemic methylprednisolone and orbital irradiation (Historical Control Group)
Number of subjects: 14
Study 6704502 — intervention group
Group type: EXPERIMENTAL
Intervention: TRM-HCT combination tablets
Number of subjects: 4
Study 6704502 — intervention group
Group type: COMPARATOR
Intervention: TRM-HCT combination capsules
Number of subjects: 4
Study 6704502 — intervention group
Group type: EXPERIMENTAL
Intervention: TRM-HCT combination product
Number of subjects: 4
Study 28301435 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic cluster sets of 4 (CS4)
Number of subjects: 8
Study 28301435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest redistribution sets of 4 (RR4)
Number of subjects: 8
Study 28301435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest redistribution sets of 1 (RR1)
Number of subjects: 8
Study 28301435 — intervention group
Group type: EXPERIMENTAL
Intervention: All protocols (CS4, RR4, RR1)
Number of subjects: 8
Study 27780819 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of whey protein per hour (PULSE)
Number of subjects: 30
Study 27780819 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g of whey protein at 0 h and 12 g of whey protein at 7 h postexercise (BOLUS)
Number of subjects: 30
Study 27780819 — intervention group
Group type: COMPARATOR
Intervention: 4 g of maltodextrin per hour (placebo)
Number of subjects: 30
Study 26200166 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics
Number of subjects: 432
Study 26200166 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics
Number of subjects: 432
Study 23618598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification of Interpretations (CBM-I) training, administered by parents over three consecutive evenings
Number of subjects: 36
Study 23618598 — intervention group
Group type: COMPARATOR
Intervention: Test-retest control group
Number of subjects: 36
Study 21862730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical breast examination (CBE)
Number of subjects: 115652
Study 21862730 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 115652
Study 20106344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study 20106344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16750207 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg every second day)
Number of subjects: 63
Study 16750207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of testosterone undecanoate and estradiol valerate (2 mg daily)
Number of subjects: 63
Study 16750207 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 63
Study 16750207 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 63
Study 16750207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (testosterone + estradiol)
Number of subjects: 63
Study 16750207 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 63
Study 16750207 — intervention group
Group type: COMPARATOR
Intervention: Estradiol treatment
Number of subjects: 63
Study 15105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent CBP (those with CBP in 1996 and 2000)
Number of subjects: 2184
Study 15105678 — intervention group
Group type: EXPERIMENTAL
Intervention: New CBP (those with CBP in 2000 but not 1996)
Number of subjects: 2184